FLT3 and acute myeloid leukemia: In a separate study of relapsed/refractory FLT3-ITD AML, sorafenib led to high response rates with resistance developing later in patients with a history of allo-HCT, and the only durable responses (i.e. >12 months) seen in post-transplant patients (78).